The infamous 2002 Women’s Health Initiative study, which set back menopause care for nearly two decades, has now been thoroughly debunked. In its wake, bioidentical hormone replacement therapy (HRT) has emerged as a celebrated solution among women’s health influencers, celebrity physicians, and cultural icons. Once confined to endocrinology and gynecology practices, HRT is now a staple in primary care, dermatology, and aesthetic medicine. This integration is more than clinical: It’s strategic. HRT offers practices a range of benefits that enhance size, stability, and scalability, making it an attractive target for private equity (PE) investors.
Read the full article: Hormones & High Returns: Why Private Equity Is Betting Big on HRT //
Source: https://vmghealth.com/insights/blog/hormones-high-returns-why-private-equity-is-betting-big-on-hrt/